Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the best management strategy to maintain remission
in patients with ANCA vasculitis who have been treated with rituximab induced B cell
depletion for at least two years. This study will compare intermittent B Cell depletion upon
B cell return or intermittent B cell depletion upon serologic relapse.